Fulcrum Therapeutics (FULC) Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last year. There are currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FULC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FULC, but not buy additional shares or sell existing shares.
View FULC analyst ratings or view top-rated stocks.

8 equities research analysts have issued 12-month price objectives for Fulcrum Therapeutics' stock. Their FULC share price forecasts range from $3.00 to $21.00. On average, they expect the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 217.5% from the stock's current price.
View analysts price targets for FULC or view top-rated stocks among Wall Street analysts.

Fulcrum Therapeutics' stock was trading at $7.28 at the beginning of 2023. Since then, FULC stock has decreased by 56.7% and is now trading at $3.15.
View the best growth stocks for 2023 here.

Fulcrum Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 3,940,000 shares, a decline of 17.6% from the April 30th total of 4,780,000 shares. Based on an average trading volume of 1,220,000 shares, the short-interest ratio is currently 3.2 days.
View Fulcrum Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our FULC earnings forecast.

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) released its earnings results on Thursday, March, 9th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.01. The company earned $0.69 million during the quarter, compared to analysts' expectations of $1.92 million. Fulcrum Therapeutics had a negative net margin of 2,687.81% and a negative trailing twelve-month return on equity of 49.35%.

ETFs with the largest weight of Fulcrum Therapeutics (NASDAQ:FULC) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).ALPS Medical Breakthroughs ETF (SBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulcrum Therapeutics investors own include VIVUS (VVUS), Provention Bio (PRVB), Entasis Therapeutics (ETTX), Kaleido Biosciences (KLDO), VBI Vaccines (VBIV), Xeris Biopharma (XERS), CymaBay Therapeutics (CBAY), Evelo Biosciences (EVLO) and Akero Therapeutics (AKRO).

(FULC) raised $76 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as the underwriters for the IPO.

Fulcrum Therapeutics trades on the NASDAQ under the ticker symbol "FULC."

Fulcrum Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (9.97%), RTW Investments LP (8.92%), Suvretta Capital Management LLC (8.38%), BlackRock Inc. (6.77%), Cowen AND Company LLC (3.52%) and Geode Capital Management LLC (1.72%). Insiders that own company stock include Christopher Morabito, Curtis Gale Oltmans, Diego Cadavid, Greg Tourangeau, James A Geraghty, Owen B Wallace, Peter G Thomson, Peter G Thomson, Ra Capital Management, LP, Robert J Gould and Robert J Gould.
View institutional ownership trends.

Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FULC stock can currently be purchased for approximately $3.15.

Fulcrum Therapeutics (NASDAQ:FULC) has a market capitalization of $194.54 million and generates $6.34 million in revenue each year. The company earns $-109,870,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis.

The company employs 104 workers across the globe.

Fulcrum Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.fulcrumtx.com. The company can be reached via phone at (617) 651-8851 or via email at christina.tartaglia@sternir.com.